Table 1.
Characteristics of the clinical participants
| Number of GC Clinical and N Participants | ||||||||
|---|---|---|---|---|---|---|---|---|
| Screening phase (16GC vs.18N) |
Training phase (58GC vs. 38N) |
Validation phase (97GC vs. 73N) |
Supplementary phase (18 pre vs. pos) |
|||||
| P value | P value | P value | P value | |||||
| GC | ||||||||
| Sex | 0.681a1 0.595a2 |
0.197a1 0.595a2 |
0.453a1 0.595a2 |
0.595a2 | ||||
| male | 10 | 41 | 69 | 15 | ||||
| female | 6 | 17 | 28 | 3 | ||||
|
Age: medium (range),y |
58 (38~71) |
0.012b1 0.209b2 |
56 (32~79) |
0.023b1 0.209b2 |
57 (22~81) |
0.000b1 0.209b2 |
61.5 (38~87) |
0.209b2 |
| TNM stage |
0.016c 0.008c 0.548c |
0.016c 0.690 c 0.056 c |
0.008c 0.690 c 0.008 c |
0.548c 0.056 c 0.008 c |
||||
| Ⅰ | 3 | 18 | 15 | 4 | ||||
| Ⅱ | 1 | 10 | 16 | 1 | ||||
| Ⅲ | 9 | 17 | 42 | 5 | ||||
| Ⅳ | 1 | 10 | 15 | 6 | ||||
| unknown | 2 | 3 | 9 | 2 | ||||
| Differentiation grade | 0.057c 0.029 c 0.686c |
0.057c 0.343 c 0.114c |
0.029 c 0.343 c 0.029 c |
0.686c 0.114 c 0.029 c |
||||
| well | 1 | 5 | 12 | 1 | ||||
| moderate | 5 | 24 | 34 | 5 | ||||
| poor | 4 | 22 | 42 | 7 | ||||
| unknown | 6 | 7 | 9 | 5 | ||||
| N | Prec | |||||||
| sex | 0.599a2 | 0.599a2 | 0.599a2 | 0.104a3 | ||||
| male | 10 | 22 | 48 | 14 | ||||
| female | 8 | 16 | 25 | 16 | ||||
|
Age: medium (range),y |
53 (25~65) |
0.292b2 | 50 (29~85) |
0.292b2 | 46 (28~71) |
0.292b2 | 58 (18~84) |
0.063b3 |
a1 Two-sided χ2 test of sex between GC and N; a2 Two-sided χ2 test of sex among GC cases in the four phases or N controls in the three phases; a3 Two-sided χ2 test of sex between Prec and N; b1 Student's-t test of age between GC and N; b2 One-way analysis of variance (ANOVA) test of age among GC cases in the four phases or N controls in the three phases; b3 Student's-t test of age between Prec and N; c Mann-Whitney U test between each of the two phases among the training, validation and supplementary phases.
Values in bold type are statistically significant (P<0.05).